Taurolidine-citrate lock solution reduces infections in pediatric cancer patients
Author Information
Author(s): Simon Arne, Ammann Roland A, Wiszniewsky Gertrud, Bode Udo, Fleischhack Gudrun, Besuden Mette M
Primary Institution: Children's Hospital Medical Center, University of Bonn, Germany
Hypothesis
The use of Taurolidine/Citrate (TauroLock™) will reduce bloodstream infections in pediatric cancer patients with central venous access devices.
Conclusion
The use of Taurolidine/Citrate (TauroLock™) significantly reduced the number and incidence density of primary catheter-associated bloodstream infections due to coagulase-negative staphylococci and methicillin-resistant staphylococci in pediatric cancer patients.
Supporting Evidence
- In group 1, 14 of 30 bloodstream infections were due to coagulase-negative staphylococci or MRSE.
- In group 2, only 3 of 25 bloodstream infections were caused by coagulase-negative staphylococci.
- The incidence density of infections in group 1 was 2.30 per 1000 CVAD utilization days, while in group 2 it was 0.45.
Takeaway
Using a special solution called TauroLock™ helps keep kids with cancer from getting sick from their catheters.
Methodology
A single center prospective cohort study comparing two groups of pediatric cancer patients over 48 months, one using heparin and the other using TauroLock™.
Limitations
The study design was historical control, which may not fully delineate the impact of the intervention.
Participant Demographics
Patients included were pediatric cancer patients with long-term central venous access devices.
Statistical Information
P-Value
0.004
Confidence Interval
95% CI, 0.09 to 1.31
Statistical Significance
p=0.004
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website